Literature DB >> 16754739

Drug therapy during labor and delivery, part 2.

Gerald G Briggs1, Stephanie R Wan.   

Abstract

PURPOSE: The drug therapy of common conditions and complications during labor and delivery and the fetal and neonatal effects of this therapy are examined.
SUMMARY: The pharmacologic therapy of common conditions that occur in labor and delivery primarily involves oxytocin and prostaglandins for cervical ripening and labor induction and systemic and regional narcotic analgesics for pain. Because most medications used in women during labor and delivery do not have Food and Drug Administration-approved labeling, pharmacists should understand the benefits and limitations of medications used in the mother. Although induction and augmentation of labor and the control of pain often require drug therapy, other, less frequent, complications may occur in labor. Drug therapies for these complications include anti-infective agents to treat maternal infection and prevent neonatal diseases; antiretrovirals to reduce perinatal HIV-1 transmission from the mother to the fetus; corticosteroids to prevent fetal lung immaturity; antihypertensives to treat preeclampsia; anticonvulsants to treat eclampsia; antibiotics to prolong pregnancy and improve neonatal outcomes after premature rupture of the membranes; tocolytics for premature labor; and oxytocin, ergot alkaloids, and prostaglandin analogues for postpartum hemorrhage. The fetal and neonatal effects of therapy for the conditions that occur during labor and delivery are usually benign, but significant morbidity and mortality involving the mother, the fetus, and the newborn are ever-present risks.
CONCLUSION: Awareness of the conditions and complications requiring drug therapy during labor and delivery will allow hospital pharmacists to make knowledgeable decisions about the rapid accessibility of critical medications in the labor and delivery unit.

Entities:  

Mesh:

Year:  2006        PMID: 16754739     DOI: 10.2146/ajhp050265.p2

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Vaginal Misoprostol for Cervical Priming before Gynaecological Procedures on Non Pregnant Women.

Authors:  Shyama Prasad Saha; Nabendu Bhattacharjee; Gangotri Baru
Journal:  Int J Health Sci (Qassim)       Date:  2007-07

2.  Cervical Priming by Misoprostol before Diagnostic Dilatation and Curettage: A Randomized Clinical Trial.

Authors:  Shima Mohammadian; Anahita Tavana; Shahrzad Tavana; Aida Mohammadian; Masoumeh Fallahian
Journal:  J Reprod Infertil       Date:  2015 Jul-Sep

3.  Assessing the efficacy of vaginal hyoscine butyl bromide on cervical ripening prior to intrauterine procedures: A double-blinded clinical trial.

Authors:  Shiva Hadadian; Masoumeh Fallahian
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-11

4.  Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women.

Authors:  Monimala Saha; Aparna Chakraborty; Sandip Chattopadhyay; Subhendu Saha; Joydip Paul; Anjan Das
Journal:  J Nat Sci Biol Med       Date:  2015-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.